Expression of D2RmRNA Isoforms and ERmRNA Isoforms in Prolactinomas: Correlation with the Response to Bromocriptine and with Tumor Biological Behavior

Overview

Journal J Neurooncol

Publisher Springer

Date 2010 Jan 12

PMID 20063113

Citations 30

Authors

Zhe Bao Wu

Wei Ming Zheng

Zhi Peng Su

Yong Chen

Jin Sen Wu

Cheng De Wang

Chen Lin

Yan Jun Zeng

Qi Chuan Zhuge

Affiliations

Soon will be listed here.

Abstract

Invasive prolactinomas are more likely to be resistant to drug therapy but the mechanism of this is still unknown. The objective of this study was to analyze the different expression of ERmRNA and D2RmRNA isoforms in prolactinomas responsive and resistant to dopamine agonist (DA), and to discuss the correlation of such gene expression with tumor biological behavior. A prospective study of 20 consecutive patients who harbored prolactinomas was designed. Patients were classified as responsive (14 cases) or resistant (six cases) according to their clinical and biochemical response to bromocriptine. Tumor tissue samples were examined by means of QRT-PCR analysis. Median D2SmRNA expression in responsive patients was about 2.5-fold that in resistant ones (13.5 +/- 10.4 and 5.4 +/- 2.4, respectively, P = 0.09). No significant difference was found between D2LmRNA expression levels (P = 0.77). However, there was a significant difference between D2S/D2LmRNA ratios for responsive and resistant tumors (P = 0.012). A significant difference was not found between these two groups in levels of ERalphamRNA and ERbetamRNA expression (P = 0.20 and 0.06, respectively). D2SmRNA expression was significantly different for invasive and noninvasive tumors (6.2 +/- 3.6 vs. 17.0 +/- 11.2, respectively, P = 0.02). The D2S/D2L ratio is related to the responsiveness of prolactinomas to DA medication, in which D2SmRNA plays an important role. Lower expression of D2SmRNA in invasive tumor patients suggests that invasive prolactinomas may be more likely to be resistant to DA medication.

Citing Articles

Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management?.

De Sousa S Endocr Oncol. 2023; 2(1):R31-R50.

PMID: 37435462 PMC: 10259306. DOI: 10.1530/EO-21-0038.

Macroprolactinoma with secondary resistance to dopamine agonists: a case report and review of the literature.

Tng E, Teo A, Aung A J Med Case Rep. 2023; 17(1):96.

PMID: 36927797 PMC: 10021939. DOI: 10.1186/s13256-023-03820-5.

DRD2 expression based on F-fallypride PET/MR predicts the dopamine agonist resistance of prolactinomas: a pilot study.

Tang H, Cheng Y, Lou X, Yao H, Xie J, Gu W Endocrine. 2023; 80(2):419-424.

PMID: 36689171 DOI: 10.1007/s12020-023-03310-0.

Transcriptomic Profiles of Normal Pituitary Cells and Pituitary Neuroendocrine Tumor Cells.

Oh J, Osorio R, Jung J, Carrete L, Choudhary N, Lad M Cancers (Basel). 2023; 15(1).

PMID: 36612109 PMC: 9817686. DOI: 10.3390/cancers15010110.

Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms.

Pivonello C, Patalano R, Negri M, Pirchio R, Colao A, Pivonello R Front Endocrinol (Lausanne). 2022; 12:791633.

PMID: 35095761 PMC: 8789681. DOI: 10.3389/fendo.2021.791633.

References

Hamilton D, Vance M, Boulos P, Laws E . Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists. Pituitary. 2006; 8(1):53-60. DOI: 10.1007/s11102-005-5086-1. View

Hayes G, Biden T, Selbie L, Shine J . Structural subtypes of the dopamine D2 receptor are functionally distinct: expression of the cloned D2A and D2B subtypes in a heterologous cell line. Mol Endocrinol. 1992; 6(6):920-6. DOI: 10.1210/mend.6.6.1323056. View

S Pereira-Lima J, Marroni C, Pizarro C, Barbosa-Coutinho L, Ferreira N, Oliveira M . Immunohistochemical detection of estrogen receptor alpha in pituitary adenomas and its correlation with cellular replication. Neuroendocrinology. 2004; 79(3):119-24. DOI: 10.1159/000077269. View

Gillam M, Molitch M, Lombardi G, Colao A . Advances in the treatment of prolactinomas. Endocr Rev. 2006; 27(5):485-534. DOI: 10.1210/er.2005-9998. View

Di Sarno A, Landi M, Cappabianca P, Di Salle F, Rossi F, Pivonello R . Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab. 2001; 86(11):5256-61. DOI: 10.1210/jcem.86.11.8054. View

Montmayeur J, Guiramand J, Borrelli E . Preferential coupling between dopamine D2 receptors and G-proteins. Mol Endocrinol. 1993; 7(2):161-70. DOI: 10.1210/mend.7.2.7682286. View

Losa M, Mortini P, Barzaghi R, Gioia L, Giovanelli M . Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. J Clin Endocrinol Metab. 2002; 87(7):3180-6. DOI: 10.1210/jcem.87.7.8645. View

Oomizu S, Boyadjieva N, Sarkar D . Ethanol and estradiol modulate alternative splicing of dopamine D2 receptor messenger RNA and abolish the inhibitory action of bromocriptine on prolactin release from the pituitary gland. Alcohol Clin Exp Res. 2003; 27(6):975-80. PMC: 2869286. DOI: 10.1097/01.ALC.0000071743.57855.BE. View

Cristina C, Diaz-Torga G, Goya R, Kakar S, Perez-Millan M, Passos V . PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes. Mol Cancer. 2007; 6:4. PMC: 1779802. DOI: 10.1186/1476-4598-6-4. View

10.

Iaccarino C, Samad T, Mathis C, Kercret H, Picetti R, Borrelli E . Control of lactotrop proliferation by dopamine: essential role of signaling through D2 receptors and ERKs. Proc Natl Acad Sci U S A. 2002; 99(22):14530-5. PMC: 137917. DOI: 10.1073/pnas.222319599. View

11.

Delgrange E, Duprez T, Maiter D . Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy. Clin Endocrinol (Oxf). 2006; 64(4):456-62. DOI: 10.1111/j.1365-2265.2006.02493.x. View

12.

Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak C . Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab. 1989; 69(3):500-9. DOI: 10.1210/jcem-69-3-500. View

13.

Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Renzo G, Merola B . Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab. 1997; 82(3):876-83. DOI: 10.1210/jcem.82.3.3822. View

14.

Trouillas J, Chevallier P, Remy C, Rajas F, Cohen R, Calle A . Differential actions of the dopamine agonist bromocriptine on growth of SMtTW tumors exhibiting a prolactin and/or a somatotroph cell phenotype: relation to dopamine D2 receptor expression. Endocrinology. 1999; 140(1):13-21. DOI: 10.1210/endo.140.1.6450. View

15.

Guivarch D, Vincent J, Vernier P . Alternative splicing of the D2 dopamine receptor messenger ribonucleic acid is modulated by activated sex steroid receptors in the MMQ prolactin cell line. Endocrinology. 1998; 139(10):4213-21. DOI: 10.1210/endo.139.10.6246. View

16.

Kovacs K, Stefaneanu L, Horvath E, Buchfelder M, Fahlbusch R, Becker W . Prolactin-producing pituitary tumor: resistance to dopamine agonist therapy. Case report. J Neurosurg. 1995; 82(5):886-90. DOI: 10.3171/jns.1995.82.5.0886. View

17.

Brue T, Pellegrini I, Gunz G, Morange I, Dewailly D, Brownell J . Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine. J Clin Endocrinol Metab. 1992; 74(3):577-84. DOI: 10.1210/jcem.74.3.1346788. View

18.

Lamberts S, Verleun T, Hofland L, Oosterom R . Differences in the interaction between dopamine and estradiol on prolactin release by cultured normal and tumorous human pituitary cells. J Clin Endocrinol Metab. 1986; 63(6):1342-7. DOI: 10.1210/jcem-63-6-1342. View

19.

Knosp E, Steiner E, Kitz K, Matula C . Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery. 1993; 33(4):610-7; discussion 617-8. DOI: 10.1227/00006123-199310000-00008. View

20.

Wu Z, Su Z, Wu J, Zheng W, Zhuge Q, Zhong M . Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion. Pituitary. 2007; 11(1):63-70. DOI: 10.1007/s11102-007-0072-4. View